Table 1.
Summary of phase II clinical trial patients, total staining score, and clinical outcome
| Patient number | Total staining score | Clinical outcome |
| 1 | 7 | PR |
| 2 | 8 | PD |
| 3 | 7 | PD |
| 4 | 6 | PD |
| 5 | 8 | PR |
| 6 | 7 | PR |
| 7 | 6 | PR |
| 8a | 9 | PR |
| 8b | 5 | PD |
| 9 | 5 | SD |
| 10 | 10 | SD |
| 11 | 8 | PD |
| 12 | 5 | PD |
| 13 | 8 | SD |
| 14 | 7 | PD |
| 15 | 7 | PR |
| 16 | 6 | SD |
| 17 | 8 | PR |
| 18 | 5 | SD |
| 19 | 7 | PR |
| 20 | 5 | PD |
Total staining scores for expression of HR23B in pretreatment biopsies from patients with advanced CTCL from the phase II trial, with the clinical outcome after treatment with SAHA indicated. PR, partial response; SD, stable disease; PD, progressive disease. The clinical and pathological criteria assessed to define PR, SD, or PD were as described in ref. 9. To determine the TSS, HR23B expression was assessed in the malignant lymphocytes in each biopsy.